Τίτλος:
Extramedullary leukemia relapse after allogeneic stem cell transplantation: A novel mechanism of immune escape?
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Relapse is a significant cause of treatment failure after allogeneic stem cell transplantation. In many cases relapse occurs when leukemic cells escape from immune surveillance. Methods &results: In the setting of haploidentical transplantation, immune escape is usually the result of the loss of the mismatched haplotype from leukemic cells, while downregulation of HLA-expression has been postulated as a significant cause of immune escape after transplantation with the use of HLA-matched donors. We observed that patients with acute leukemia who relapse at the time of active graft-versus-host-disease, usually develop extramedullary leukemia while they remain free of leukemia in peripheral blood and bone marrow. Conclusion: Our observation points toward a novel mechanism of immune escape which is microenvironment-specific. © 2020 Future Medicine Ltd.
Συγγραφείς:
Gkirkas, K.
Stamouli, M.
Karagiannidou, A.
Chondropoulos, S.
Tsirigotis, P.
Περιοδικό:
Journal of Immunotherapy
Εκδότης:
Future Medicine Ltd
Λέξεις-κλειδιά:
azacitidine; cyclosporine; cytarabine; fludarabine; granulocyte colony stimulating factor; HLA antigen; idarubicin; nivolumab; sorafenib, acute graft versus host disease; acute lymphoblastic leukemia; acute myeloid leukemia; adult; allogeneic stem cell transplantation; antigen expression; Article; cancer regression; donor; donor lymphocyte infusion; down regulation; female; haploidentical transplantation; haplotype; HLA matching; human; leukemia cell; leukemia relapse; major clinical study; male; middle aged; mortality; myelodysplastic syndrome; priority journal; treatment outcome; tumor escape; tumor microenvironment; allograft; graft versus host reaction; immunology; leukemia; procedures; recurrent disease; stem cell transplantation, Adult; Allografts; Female; Graft vs Host Disease; Humans; Leukemia; Male; Middle Aged; Recurrence; Stem Cell Transplantation; Treatment Outcome
DOI:
10.2217/imt-2019-0215
